UK cancer drug developer, Antisoma, says that it has started a Phase II clinical trial of its small-molecule vascular targeting agent, AS1404, in recurrent ovarian cancer.

The trial in question aims to include around 70 patients, with half receiving standard chemotherapy regimen of carboplatin, and Bristol-Myers Squibb’s Taxol (paclitaxel), and the other half receiving the same treatment plus AS1404. Response rates, time to tumour progression and survival will be compared.

AS1404 works by attacking established tumour blood vessels and is thought to have potential against a wide variety of cancer types. It is also undergoing Phase II testing in the treatment of lung and prostate cancers, with the first efficacy data expected from the lung study during the second half of this year [[16/09/04e]].